Dr. Reddy's Laboratories Stock Forecast, Price & News

-1.42 (-2.14 %)
(As of 09/20/2021 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume1,770 shs
Average Volume155,245 shs
Market Capitalization$10.80 billion
P/E Ratio41.62
Dividend Yield0.42%
30 days | 90 days | 365 days | Advanced Chart
Receive RDY News and Ratings via Email

Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Dr. Reddy

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.75 out of 5 stars

Medical Sector

827th out of 1,352 stocks

Pharmaceutical Preparations Industry

408th out of 665 stocks

Analyst Opinion: 1.3Community Rank: 3.9Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Dr. Reddy's Laboratories (NYSE:RDY) Frequently Asked Questions

Is Dr. Reddy's Laboratories a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dr. Reddy's Laboratories in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Dr. Reddy's Laboratories stock.
View analyst ratings for Dr. Reddy's Laboratories
or view top-rated stocks.

What stocks does MarketBeat like better than Dr. Reddy's Laboratories?

Wall Street analysts have given Dr. Reddy's Laboratories a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Dr. Reddy's Laboratories wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 1,170,000 shares, an increase of 17.6% from the July 29th total of 995,200 shares. Based on an average trading volume of 109,900 shares, the days-to-cover ratio is presently 10.6 days. Currently, 0.7% of the shares of the company are short sold.
View Dr. Reddy's Laboratories' Short Interest

When is Dr. Reddy's Laboratories' next earnings date?

Dr. Reddy's Laboratories is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for Dr. Reddy's Laboratories

How were Dr. Reddy's Laboratories' earnings last quarter?

Dr. Reddy's Laboratories Limited (NYSE:RDY) announced its quarterly earnings data on Tuesday, July, 27th. The company reported $0.46 EPS for the quarter, missing the consensus estimate of $0.55 by $0.09. The business had revenue of $662 million for the quarter, compared to analysts' expectations of $685.22 million. Dr. Reddy's Laboratories had a net margin of 9.81% and a trailing twelve-month return on equity of 13.92%.
View Dr. Reddy's Laboratories' earnings history

How has Dr. Reddy's Laboratories' stock been impacted by COVID-19?

Dr. Reddy's Laboratories' stock was trading at $40.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RDY shares have increased by 61.6% and is now trading at $64.93.
View which stocks have been most impacted by COVID-19

How often does Dr. Reddy's Laboratories pay dividends? What is the dividend yield for Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories announced an annual dividend on Wednesday, June 16th. Shareholders of record on Friday, July 9th will be paid a dividend of $0.285 per share on Friday, July 9th. This represents a yield of 0.4%. The ex-dividend date of this dividend is Thursday, July 8th.
View Dr. Reddy's Laboratories' dividend history

Is Dr. Reddy's Laboratories a good dividend stock?

Dr. Reddy's Laboratories pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.42%. The dividend payout ratio of Dr. Reddy's Laboratories is 13.93%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 8.05% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.
View Dr. Reddy's Laboratories' dividend history.

What price target have analysts set for RDY?

3 analysts have issued 1 year target prices for Dr. Reddy's Laboratories' stock. Their forecasts range from $63.41 to $70.00. On average, they anticipate Dr. Reddy's Laboratories' stock price to reach $66.71 in the next twelve months. This suggests a possible upside of 2.7% from the stock's current price.
View analysts' price targets for Dr. Reddy's Laboratories
or view top-rated stocks among Wall Street analysts.

Who are Dr. Reddy's Laboratories' key executives?

Dr. Reddy's Laboratories' management team includes the following people:
  • Erez Israeli, Chief Executive Officer
  • Parag Agarwal, Chief Financial Officer
  • Mukesh Rathi, Chief Digital & Information Officer
  • Sandeep Poddar, Secretary & Compliance Officer
  • M. V. Ramana, CEO-India & Emerging Markets Branded Markets

What is G. V. Prasad's approval rating as Dr. Reddy's Laboratories' CEO?

528 employees have rated Dr. Reddy's Laboratories CEO G. V. Prasad on Glassdoor.com. G. V. Prasad has an approval rating of 96% among Dr. Reddy's Laboratories' employees. This puts G. V. Prasad in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Dr. Reddy's Laboratories' key competitors?

What other stocks do shareholders of Dr. Reddy's Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Tata Motors (TTM), Infosys (INFY), Vedanta (VEDL), HDFC Bank (HDB), Alibaba Group (BABA), GlaxoSmithKline (GSK), Merck & Co., Inc. (MRK), NVIDIA (NVDA) and Pfizer (PFE).

What is Dr. Reddy's Laboratories' stock symbol?

Dr. Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

Who are Dr. Reddy's Laboratories' major shareholders?

Dr. Reddy's Laboratories' stock is owned by many different institutional and retail investors. Top institutional shareholders include Royal Bank of Canada (2.00%), Renaissance Technologies LLC (1.21%), BlackRock Inc. (0.81%), Vanguard Group Inc. (0.67%), State Street Corp (0.51%) and Bank of Montreal Can (0.42%).

Which major investors are selling Dr. Reddy's Laboratories stock?

RDY stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Grantham Mayo Van Otterloo & Co. LLC, Mitsubishi UFJ Trust & Banking Corp, Morgan Stanley, Morgan Stanley, State Street Corp, Sei Investments Co., and Royal Bank of Canada.

Which major investors are buying Dr. Reddy's Laboratories stock?

RDY stock was bought by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, Vanguard Group Inc., Fiera Capital Corp, Goldman Sachs Group Inc., Canada Pension Plan Investment Board, Amundi, Northern Trust Corp, and BlackRock Inc..

How do I buy shares of Dr. Reddy's Laboratories?

Shares of RDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dr. Reddy's Laboratories' stock price today?

One share of RDY stock can currently be purchased for approximately $64.93.

How much money does Dr. Reddy's Laboratories make?

Dr. Reddy's Laboratories has a market capitalization of $10.80 billion and generates $2.59 billion in revenue each year. The company earns $236 million in net income (profit) each year or $2.01 on an earnings per share basis.

How many employees does Dr. Reddy's Laboratories have?

Dr. Reddy's Laboratories employs 2,021 workers across the globe.

When was Dr. Reddy's Laboratories founded?

Dr. Reddy's Laboratories was founded in 1984.

What is Dr. Reddy's Laboratories' official website?

The official website for Dr. Reddy's Laboratories is www.drreddys.com.

Where are Dr. Reddy's Laboratories' headquarters?

Dr. Reddy's Laboratories is headquartered at 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034.

How can I contact Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company can be reached via phone at 914049002900 or via email at [email protected].

This page was last updated on 9/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.